Estland - estniska - Ravimiamet

zentiva k.s. - sorafeniib - õhukese polümeerikattega tablett - 200mg 112tk

Estland - estniska - Ravimiamet

sandoz pharmaceuticals d.d. - sorafeniib - õhukese polümeerikattega tablett - 400mg 84tk; 400mg 56tk; 400mg 112tk; 400mg 30tk; 400mg 28tk

Estland - estniska - Ravimiamet

lv system service sia - sorafeniib - õhukese polümeerikattega tablett - 200mg 112tk

Europeiska unionen - estniska - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastilised ained - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Estland - estniska - Ravimiamet

takeda pharma as - lornoksikaam - õhukese polümeerikattega tablett - 4mg 100tk; 4mg 50tk; 4mg 250tk; 4mg 20tk; 4mg 10tk; 4mg 30tk

Estland - estniska - Ravimiamet

takeda pharma as - lornoksikaam - õhukese polümeerikattega tablett - 8mg 6tk; 8mg 20tk; 8mg 100tk; 8mg 50tk; 8mg 30tk

Estland - estniska - Ravimiamet

takeda pharma as - lornoksikaam - süstelahuse pulber ja lahusti - 8mg 5tk; 8mg 10tk; 8mg 1tk

Estland - estniska - Ravimiamet

takeda pharma as - lornoksikaam - õhukese polümeerikattega tablett - 8mg 500tk; 8mg 100tk; 8mg 30tk; 8mg 250tk; 8mg 50tk

Estland - estniska - Ravimiamet

first pharma oÜ - lornoksikaam - õhukese polümeerikattega tablett - 8mg 20tk

Estland - estniska - Ravimiamet

first pharma oÜ - lornoksikaam - õhukese polümeerikattega tablett - 8mg 50tk; 8mg 20tk; 8mg 30tk; 8mg 100tk; 8mg 6tk